Skip to content

A Nutritional Approach to Minimal Hepatic Encephalopathy

A Nutritional Approach to Minimal Hepatic Encephalopathy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01083446
Enrollment
60
Registered
2010-03-09
Start date
2008-07-31
Completion date
2010-08-31
Last updated
2010-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimal Hepatic Encephalopathy

Keywords

Encephalopathy, Cirrhotics

Brief summary

This trial will study a possible effect of standard Israeli breakfast (30% of caloric value and 21 gram protein) on cognitive and executive functions (working memory, visual memory, concentration and coordination), on patients with mild-moderate liver cirrhosis.

Interventions

OTHERNutritional Intervention

Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)

Sponsors

Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All consented adults (age \> 18), with the diagnosis of CHILD A cirrhosis with MELD score of \< 10. * Diagnosis of liver cirrhosis as documented by liver biopsy (stage IV) and / or fibroscan (score \> 12 kpa) and / or fibrotest (score \> 0.74) and /or imaging.

Exclusion criteria

* History of \> grade II hepatic encephalopathy (HE). * Diagnosis of dementia, Parkinson disease, Schizophrenia (Patients with major depression will be noted but not excluded). * Use of sedatives, tranquilizers or anti- psychotic medication during and/or 2 weeks prior to enrolling Use of antibiotics for any length of period during and/or 2 weeks prior to enrolling. * Current use of lactulose or neomycin. * Use of alcohol or elicit drugs during and/ or 6 months prior to enrolling.

Countries

Israel

Contacts

Primary ContactNachum Vaisman, Prof'
vaisman@tasmc.health.gov.il+972-3-6974807

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026